Flywire Corp. is a payments enablement and software company. The firm engages in providing vertical-specific software and payments technology to embed within the existing accounts receivable (AR) workflows for clients across the education, healthcare, travel vertical markets, and business-to-business (B2B) industries. It also integrates with enterprise resource planning (ERP) systems, such as NetSuite, which allows organizations to optimize the payment experience of customers. The company was founded by Marcaide Marchite Iker in July 2009 and is headquartered in Boston, MA.
CEO & DirectorMr. Michael Massaro
President & COOMr. Robert Orgel J.D.
Chief Financial OfficerMr. Cosmin Pitigoi
Vice President of Investor RelationsMs. Maria Leonidovna Kahn C.F.A.
General Counsel & Chief Compliance OfficerMr. Peter Butterfield J.D.
PAR Technology Corp. engages in the provision of omnichannel cloud-based software and hardware solutions to the restaurant industry in three major restaurant categories, which are quick service, fast casual, and table service. The company was founded by John W. Sammon, Jr. in 1968 and is headquartered in New Hartford, NY.
CEOMr. Savneet Singh
CFO & VPMr. Bryan A. Menar CPA
Chief Legal Officer & Corporate SecretaryMs. Catherine A. King J.D.
Chief Accounting OfficerMr. Michael Anthony Steenberge
Senior Vice President of Investor Relations & Business DevelopmentMr. Christopher R. Byrnes
Xponential Fitness, Inc. is a curator of boutique fitness brands across multiple verticals. It operates as a boutique fitness franchisor in the United States with studios operating across distinct brands. The company's portfolio of brands spans a variety of fitness and wellness verticals, including cycling, stretch, rowing, yoga, boxing, dance and running. Its brands include Club Pilates, Pure Barre, CycleBar, StretchLab, Row House, YogaSix Rumble, AKT, and STRIDE. The company was founded on August 11, 2017 and is headquartered in Irvine, CA.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
CEODr. James Brian Windsor Ph.D.
M.B.A.Mr. Timothy M. Cunningham CPA
Chief Scientific OfficerDr. Cory M. Hogaboam Ph.D.
CounselMs. Jennifer Faigle
VP of Finance and Corporate ControllerMr. Ron Chen
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, alerts, and much more.